Product label
Regulatory context; not efficacy evidence
Adults with erythropoietic protoporphyria meeting the Scenesse implant label.
Reported findings. Scenesse has indication-specific approval to increase pain-free light exposure.
Nonresponse. Nonresponse frequency not established in this excerpt.
Harms. Implant reactions, nausea, skin/melanocytic changes; not research-vial safety.
Limits. The approved implant is not interchangeable with a research vial or nasal spray. Melanotan I and Melanotan II are distinct.
Preparation: Scenesse controlled-release afamelanotide implant Route: subcutaneous implant
Read original source ↗Editorial review 2026-10-09. Clinician review pending.